117 related articles for article (PubMed ID: 27757529)
1. Efficacy of Yeast' Vacuoles as Antimicrobial Agents to Escherichia coli Bacteremia in Rat.
Yoon J; Cho HS; Park C; Park BY; Kim YH; Min J
Curr Microbiol; 2017 Jan; 74(1):22-27. PubMed ID: 27757529
[TBL] [Abstract][Full Text] [Related]
2. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.
Tan XX; Actor JK; Chen Y
Antimicrob Agents Chemother; 2005 Aug; 49(8):3203-7. PubMed ID: 16048926
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of Berberis aristata against peritonitis induced by carbapenem-resistant Escherichia coli in a mammalian model.
Thakur P; Chawla R; Narula A; Sharma RK
J Glob Antimicrob Resist; 2017 Jun; 9():21-29. PubMed ID: 28323228
[TBL] [Abstract][Full Text] [Related]
4. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models.
Szabo D; Ostorhazi E; Binas A; Rozgonyi F; Kocsis B; Cassone M; Wade JD; Nolte O; Otvos L
Int J Antimicrob Agents; 2010 Apr; 35(4):357-61. PubMed ID: 20031377
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
6. The impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia.
Wang KC; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2016 Oct; 49(5):768-774. PubMed ID: 26493889
[TBL] [Abstract][Full Text] [Related]
7. Characterization of antimicrobial activity of the lysosomes isolated from Saccharomyces cerevisiae.
Yoon J; Park JM; Jung SK; Kim KY; Kim YH; Min J
Curr Microbiol; 2009 Jul; 59(1):48-52. PubMed ID: 19319596
[TBL] [Abstract][Full Text] [Related]
8. Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
Blot S; Vandijck D; Vandewoude K; Depuydt P; Vogelaers D; Peleman R
J Antimicrob Chemother; 2007 Dec; 60(6):1402. PubMed ID: 17913718
[No Abstract] [Full Text] [Related]
9. Ceftriaxone treatment failure in cephalosporin-susceptible Escherichia coli bacteraemia.
Papanicolas LE; Bell JM; Weldhagen GF; Bastian I
Int J Antimicrob Agents; 2013 Mar; 41(3):298-9. PubMed ID: 23312600
[No Abstract] [Full Text] [Related]
10. Antimicrobial susceptibility in Escherichia coli of human and avian origin--a comparison of wild-type distributions.
Sjölund M; Bengtsson S; Bonnedahl J; Hernandez J; Olsen B; Kahlmeter G
Clin Microbiol Infect; 2009 May; 15(5):461-5. PubMed ID: 19260874
[TBL] [Abstract][Full Text] [Related]
11. [Escherichia coli a forgotten pathogen in septicemia].
Sledzińska A; Samet A; Bronk M; Rybak B; Kur J; Krawczyk B; Nowicki B
Przegl Epidemiol; 2006; 60(1):27-34. PubMed ID: 16758735
[TBL] [Abstract][Full Text] [Related]
12. [Sensitivity for antibiotics among the E. coli strains isolated from patients with different clinical stage of infection].
Kicińska AM; Lichodziejewska-Niemierko M; Bronk M; Sledzińska A; Samet A; Rutkowski B
Przegl Lek; 2012; 69(6):217-21. PubMed ID: 23094431
[TBL] [Abstract][Full Text] [Related]
13. Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
Hwang KP; Tang YF; Shen YH
J Microbiol Immunol Infect; 2009 Oct; 42(5):433-8. PubMed ID: 20182674
[TBL] [Abstract][Full Text] [Related]
14. Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia.
Opal SM; Palardy JE; Parejo N; Jasman RL
Crit Care Med; 2003 Mar; 31(3):929-32. PubMed ID: 12627007
[TBL] [Abstract][Full Text] [Related]
15. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
[TBL] [Abstract][Full Text] [Related]
16. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
17. Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model.
Skorup P; Maudsdotter L; Lipcsey M; Castegren M; Larsson A; Jonsson AB; Sjölin J
PLoS One; 2014; 9(2):e90441. PubMed ID: 24587365
[TBL] [Abstract][Full Text] [Related]
18. Septicemia due to multiple biotypes of Escherichia coli.
Amstey MS; Casian-Colón AE
Obstet Gynecol; 1997 Oct; 90(4 Pt 2):667-8. PubMed ID: 11770588
[TBL] [Abstract][Full Text] [Related]
19. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections.
Helfand MS; Bonomo RA
Clin Infect Dis; 2006 Dec; 43(11):1415-6. PubMed ID: 17083013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
